Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Monotherapy in MSI-H/dMMR Solid Tumors
NCT03941574Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Jul 2019
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in solid tumor, sponsored by Henlius. Primary endpoint: Objective Response Rate up to 2 years. Started Jul 2019; status: recruiting.
02
Drugs
serplulimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03941574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941574.